Highlights
- 1Gastroenterology · 2020
- 2Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
- 3
Publications
85 publications
Funding
17 grants
Active
5 grants- Co-IBP 231752-01Molecular and clinical characterization of IBD patients naive or refractory to standard of care over timeBoehringer Ingelheim Pharmaceuticals, Inc. (Germany) · 2023–2028BioPharma Alliance
- Sub-PIU01DK134321-04Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled TrialNational Institute of Diabetes and Digestive and Kidney Diseases · 2023–2028 · via Northwestern University
- Co-ICCFA #1454068Histological Predictors of Recurrence in Crohn's Disease: A Multicenter StudyCrohn's and Colitis Foundation of America · 2025–2026
- PICCFA 253416-01IBD-STARTCrohn's and Colitis Foundation of America · 2025–2026
- Sub-PIU01DK138901-02Utility of Random Biopsies in Inflammatory Bowel DiseaseNational Institute of Diabetes and Digestive and Kidney Diseases · 2024–2026 · via University of Pennsylvania
Completed grants (12)
- Sub-PICCF 862881CHASE-EIM: Cohort for Healing Arthritis, Skin, and Eye Extra-Intestinal ManifestationsCrohn's and Colitis Foundation of America · 2022–2025 · via Cleveland Clinic Foundation
- PIUP 251515-01AGA EMPOWER-IBD: Clinical Effectiveness Factorial Randomization TrialUniversity of Pennsylvania · 2024–2025Contract
- KP1148765Real-World Evaluation of Combination Biologic or Small Molecule Therapy Among Patients with Inflammatory Bowel DiseaseCrohn's and Colitis Foundation of America · 2023–2023
- PIFEL-005969Advanced Fellowship in Inflammatory Bowel Disease, Jill Roberts Center For IBDTakeda Pharmaceutical Company · 2022–2023
- PIJS FS20673Weill Cornell Medicine Advanced IBD Fellowship 2021-22Janssen Scientific · 2021–2023Fellowship
- PIKRF 2019-1435The Impact of Time Restricted Feeding in Crohn's DiseaseKenneth Rainin Foundation · 2019–2022
- PIAVI 214545-01Advanced Fellowship in Inflammatory Bowel Disease, Jill Roberts Center For IBD, Weill Cornell MedicineAbbVie Inc. · 2021–2022Fellowship
- PIFEL-001884Weill Cornell Advanced Fellowship in Inflammatory Bowel DiseaseTakeda Pharmaceutical Company · 2021–2022
- PIAI 209494-01Advanced Fellowship in Inflammatory Bowel Disease New York Presbyterian Hospital-Weill Cornell Medicine Weill Cornell Medical College Jill Roberts Center for Inflammatory Bowel DiseaseAbbVie Inc. · 2020–2021
- PIIBD Grant FEL-61906Advanced Fellowship in Inflammatory Bowel Disease New York Presbyterian Hospital-Weill Cornell Medicine Weill Cornell Medical College Jill Roberts Center for Inflammatory Bowel DiseaseTakeda Pharmaceutical Company · 2020–2021
- PIAbbVie INC. #FEL-59794Weill Cornell Medical College Advanced Fellowship Training in Inflammatory Bowel DiseaseAbbVie Inc. · 2020–2020Fellowship
- PITP FEL-59794Weill Cornell Medical College Advanced Fellowship Training in Inflammatory Bowel DiseaseTakeda Pharmaceutical Company · 2019–2020
Clinical research
24 studies
Active
11 studies- PINCT07652294A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants With Inflammatory Bowel DiseasePHASE2 · Spyre Therapeutics INC · OPEN TO ACCRUAL (as of 2026)Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis; Colitis, Ulcerative
- PINCT06560021A Randomized Trial of the Utility of Random Biopsies in Patients With Inflammatory Bowel DiseaseNA · University of Pennsylvania · OPEN TO ACCRUAL (as of 2026)Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis
- PINCT07012395Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative ColitisPHASE2 · Spyre Therapeutics INC · OPEN TO ACCRUAL (as of 2026)Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis; Colitis, Ulcerative
- PINCT06095128An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative ColitisPHASE4 · Takeda Development Center Americas, Inc. · OPEN TO ACCRUAL (as of 2025)Ulcerative Colitis
- PIComprehensive Evaluation of COMBination Advanced Therapy to Achieve Treat-To-Target Endpoints Among Inflammatory Bowel Disease Patients with Inadequate Response to Optimized Monotherapy (COMBAT-IBD)Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIOutcomes of Patients with Inflammatory Bowel Disease and Hidradenitis Suppurativa: A multicenter retrospective chart reviewWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
- PINCT05230173Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic RemissionNA · University of California, San Diego · OPEN TO ACCRUAL (as of 2023)Ulcerative Colitis; Crohn Disease
- PIChase EIM - Cohort for Healing Arthritis, Skin, and Eye Extra-Intestinal ManifestationsCrohn's & Colitis Foundation of America, Inc. · OPEN TO ACCRUAL (as of 2023)
- PINCT04897282Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI In-vitro Diagnostics Device to Detect Treatment Response Measured by Endoscopic Healing in Moderate to Severe Ulcerative Colitis Patients Treated With Anti-TNF-a.Glycominds, LLC · OPEN TO ACCRUAL (as of 2021)Ulcerative Colitis
- PIIBD Qorus: Improving the Quality of Care for Adults with Inflammatory Bowel DiseaseCrohn's & Colitis Foundation of America, Inc. · OPEN TO ACCRUAL (as of 2021)
- PIInflammatory Bowel Diseases DatamartWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
Completed & closed trials (13)
- PINCT04835506Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE TrialPHASE4 · Beth Israel Deaconess Medical Center, Inc. · IRB STUDY CLOSURE (as of 2026)Crohn Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
- PINCT06109441Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic TherapyPHASE2 · AltruBio, Inc. · CLOSED TO ACCRUAL (as of 2025)Ulcerative Colitis
- PINCT04259138VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment TargetPHASE4 · Alimentiv Inc. · IRB STUDY CLOSURE (as of 2025)Colitis, Ulcerative
- PINCT04847739Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)PHASE2 · Avobis Bio, LLC · IRB STUDY CLOSURE (as of 2025)Perianal Fistula; Crohn's Disease
- PINCT05370885Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative ColitisPHASE2 · Vedanta Biosciences, Inc. · IRB STUDY CLOSURE (as of 2025)Ulcerative Colitis; Colitis, Ulcerative
- PINCT05466890Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative ColitisPHASE2 · Palatin Technologies, Inc. · IRB STUDY CLOSURE (as of 2025)Ulcerative Colitis; Ulcerative Colitis Acute; Ulcerative; Ulcerative Colitis Flare
- PITracking Sexual Dysfunction Over Time in Patients with Inflammatory Bowel DiseaseNew York University · IRB STUDY CLOSURE (as of 2024)
- PIPredicting Crohn?s & Colitis Outcomes in the United StatesPredictImmune Ltd · IRB STUDY CLOSURE (as of 2023)
- PINCT04672161Education Intervention on Vaccination Adherence Among IBD Patients at Weill Cornell Medical CenterNA · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)Crohn Disease (CD); Ulcerative Colitis (UC); Indeterminate Colitis
- PINCT03765450Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative ColitisRobarts Clinical Trials Inc · IRB STUDY CLOSURE (as of 2023)Ulcerative Colitis
- PINCT04271748The Impact of Time Restricted Feeding in Crohn's DiseaseNA · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2022)Crohn's Disease (CD)
- PIAssessment of clinical and endoscopic scores in post-resection inflammatory bowel disease patients with small intestinal bacterial overgrowth, bile acid malabsorption or fat malabsorption.Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
- PINCT05013385Multi-center, Double-blind, Randomized, Placebo-controlled, Phase IIa Trial to Evaluate Spesolimab (BI 655130) Efficacy in Patients With Fibrostenotic Crohn's DiseasePHASE2 · Boehringer Ingelheim Pharmaceuticals, Inc. (Germany) · IRB STUDY CLOSURE (as of 2022)Fibrostenotic Crohn´s Disease
Mentoring
3 menteesAll publications with mentees →
- ELEsther LiuMD mentee · Class of 2024
- CYCaroline YoungMD mentee · Class of 2026
- JJJacob JamisonMD mentee · Class of 2026
External relationships
Leadership Roles
AbbVie Inc. · Janssen Scientific Affairs, LLC · Pfizer, Inc.
Advisory/Scientific Board Member
Vedanta Biosciences, Inc.
Speaker/Lecturer
AbbVie Inc.
Other Interest
Eli Lilly and Company · Takeda Pharmaceutical Company Limited
Other
AbbVie Inc. · AltruBio, Inc. · Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · Janssen Scientific Affairs, LLC · Palatin Technologies, Inc. · Pfizer, Inc.